Diligence memo · auto-generated · as of July 2, 2026

Synthonics Inc

Synthonics Inc looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Synthonics Inc operates in Biotechnology, based in BLACKSBURG.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Synthonics Inc has raised $3.5M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.6M on 2010-08-09.

Most recent recorded round closed around 2014-07-11.

Valuation (modeled)modeled

Provath models Synthonics Inc at approximately $22M (range $360K–$174M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.33× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 29 months.

Last raise 12.0 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 5.2× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 36% of Biotechnology peers (4293 compared).

Modeled value ranks above 30% of those peers.

Closest niche peers: Harpoon Medical, Inc., Admittance Technologies, Inc., Bell Biosystems, Inc., Nexstim Plc, Iontera, Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.